The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
The ten-day initiative, running from 10 to 21 November, brings together a team of highly skilled German doctors providing life-changing reconstructive surgeries at no cost
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Diversifying its portfolio to include late-phase antiviral agent
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Fenebrutinib targets cells in the immune system known as B cells and microglia
Subscribe To Our Newsletter & Stay Updated
